| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00280-017-3478-3 |
| P698 | PubMed publication ID | 29134491 |
| P50 | author | Mohammad Safiqul Islam | Q57921212 |
| Noor Ahmed Nahid | Q57945060 | ||
| Mohd Nazmul Hasan Apu | Q88174652 | ||
| P2093 | author name string | Abul Hasnat | |
| Maizbha Uddin Ahmed | |||
| Zabun Nahar | |||
| Md Siddiqul Islam | |||
| Md Reazul Islam | |||
| Samia Shabnaz | |||
| Surid Mohammad Chowdhury | |||
| P2860 | cites work | Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 |
| Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure | Q24296496 | ||
| A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase | Q24324172 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Fluorinated pyrimidines, a new class of tumour-inhibitory compounds | Q28214124 | ||
| A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency | Q28294735 | ||
| Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients | Q28474358 | ||
| Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. | Q30360930 | ||
| Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale | Q33366660 | ||
| Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma | Q33384217 | ||
| Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis | Q33419230 | ||
| Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients | Q33696582 | ||
| Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer | Q33810043 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity | Q34216563 | ||
| Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. | Q34636318 | ||
| Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial | Q34637479 | ||
| Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years | Q34637749 | ||
| Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. | Q34775315 | ||
| Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients | Q34991668 | ||
| Pharmacogenetics and pharmacogenomics of anticancer agents. | Q35030489 | ||
| Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration | Q35891732 | ||
| Adjuvant therapy of colon cancer: current status and future directions. | Q36874669 | ||
| Metastatic colorectal cancer: current systemic treatment options. | Q36920617 | ||
| Pharmacogenetic relevance of MTHFR polymorphisms | Q37264528 | ||
| Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. | Q37345347 | ||
| Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity | Q37358027 | ||
| Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer | Q37780865 | ||
| DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis | Q38127715 | ||
| Clinical pharmacology of 5-fluorouracil | Q38631279 | ||
| Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity | Q38796384 | ||
| 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency | Q40275788 | ||
| Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate | Q40597353 | ||
| Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity | Q42544952 | ||
| Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? | Q43882551 | ||
| Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. | Q45193940 | ||
| Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity | Q45285628 | ||
| Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene | Q46502256 | ||
| Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group | Q46733975 | ||
| Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. | Q46775241 | ||
| Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. | Q54282377 | ||
| P433 | issue | 1 | |
| P921 | main subject | colorectal cancer | Q188874 |
| fluorouracil | Q238512 | ||
| P304 | page(s) | 119-129 | |
| P577 | publication date | 2017-11-13 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer | |
| P478 | volume | 81 |
Search more.